Yao, L. Sun, J. Hu, L. Chen, J. Zhang, J. Xu, Y. Xie, Y#. Ovarian cancer risk of Chinese women with BRCA1/2 germline pathogenic variants,Journal of human genetics,67(11):639-42

Tan, Y. Yao, L. Gamliel, A. Nair, S. J. Taylor, H. Ohgi, K. Aggarwal, A. K. Rosenfeld, M. G*. Signal-induced enhancer activation requires Ku70 to read topoisomerase1-DNA covalent complexes,Nat Struct Mol Biol,30(2):148-58

Zang, F#. Ding, X#. Chen, J. Hu, L. Sun, J. Zhang, J. Xu, Y. Yao, L*. Xie, Y*. Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype,Breast Cancer Res Treat,195(3):431-9

Liu X#, Wang Y#, Cao K#, Yao L#, Hu L, Sun J, Zhang J, Xu Y, Xie Y*. Impact of multifocal or multicentric disease on local recurrence and survival in breast cancer patients with or without BRCA1/2 variants,Breast Cancer Res Treat,199(1):25-33

Zhang, J#. Yao, L#. Liu, Y. Ouyang, T. Li, J. Wang, T. Fan, Z. Fan, T. Lin, B. Xie, Y*. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer,Int J Cancer,2021.148: 941-9

Meng, H#. Yao, L#. Yuan, H#. Xu, Y. Ouyang, T. Li, J. Wang, T. Fan, Z. Fan, T. Lin, B. Xie, Y*. BRCA1 c.5470_5477del, a founder mutation in Chinese Han breast cancer patients,Int J Cancer,2020. 146: 3044-52

Fu, F#. Zhang, D#. Hu, L#. Sundaram, S. Ying, D. Zhang, Y. Fu, S. Zhang, J. Yao, L. Xu, Y. Xie, Y*. Association between 15 known or potential breast cancer susceptibility genes and breast cancer risks in Chinese women,Cancer Biol Med,

家族遗传性乳腺癌

BARD1胚系突变在乳腺癌DNA损伤应答中的作用及潜在临床意义, 课题负责人, 2023.1.1～2026.12.31, 国家自然科学基金面上项目

中国人群特异BRCA1/2重复突变的乳腺癌发病风险评估及功能研究, 课题负责人, 2017.1.1～2020.12.31, 国家自然科学基金面上项目

DNA修复基因致病性突变对乳腺癌新辅助化疗疗效的预测作用, 课题负责人, 2021.1.1～2023.12.31, 北京市医管局培育项目

中国家族性乳腺癌BRCA1/2基因大片段重排断裂位点鉴定及功能研究, 参加者, 2018.1.1～2021.12.31, 国家自然科学基金面上项目

研究生招生计划

招生年度	招生专业	学位级别	学位类型	研究方向	选拔方式	操作
2025	肿瘤学	硕士	科学学位	遗传性乳腺癌	全国统考